{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:18:43Z","timestamp":1781169523292,"version":"3.54.1"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["315824"],"award-info":[{"award-number":["315824"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.biopha.2022.112652","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T20:00:52Z","timestamp":1642622452000},"page":"112652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Profiling the regulatory interplay of BET bromodomains and Sirtuins in cancer cell lines"],"prefix":"10.1016","volume":"147","author":[{"given":"Joni","family":"J\u00e4rvenp\u00e4\u00e4","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Rahnasto-Rilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"Lahtela-Kakkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenni","family":"K\u00fcblbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.112652_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.112652_bib2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in obesity, inflammation and cancer","volume":"12","author":"Belkina","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2022.112652_bib3","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018762","article-title":"Writers and readers of histone acetylation: structure, mechanism, and inhibition","volume":"6","author":"Marmorstein","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2022.112652_bib4","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399411001992","article-title":"Bromodomains as therapeutic targets","volume":"13","author":"Muller","year":"2011","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.biopha.2022.112652_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.005","article-title":"Bromodomains: Structure, function and pharmacology of inhibition","volume":"106","author":"Ferri","year":"2016","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.biopha.2022.112652_bib6","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2022.112652_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2022.112652_bib8","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"BET inhibitors: a novel epigenetic approach","volume":"28","author":"Doroshow","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2022.112652_bib9","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1021\/jm4014407","article-title":"The Making of I-BET762, a BET bromodomain inhibitor now in clinical development","volume":"56","author":"Zhao","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.112652_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histone deacetylases (HDACs) in human cancer","volume":"1","author":"Ropero","year":"2007","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.biopha.2022.112652_bib11","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/cbic.201500272","article-title":"BET inhibition upregulates SIRT1 and alleviates inflammatory responses","volume":"16","author":"Kokkola","year":"2015","journal-title":"Chembiochem"},{"key":"10.1016\/j.biopha.2022.112652_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.freeradbiomed.2012.10.525","article-title":"Seven sirtuins for seven deadly diseases of aging","volume":"56","author":"Morris","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.biopha.2022.112652_bib13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nrc3985","article-title":"The multifaceted functions of sirtuins in cancer","volume":"15","author":"Chalkiadaki","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2022.112652_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fphar.2019.00038","article-title":"Dual tumor suppressor and tumor promoter action of sirtuins in determining malignant phenotype","volume":"10","author":"Carafa","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112652_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bcp.2016.04.009","article-title":"Inhibition of BET bromodomains alleviates inflammation in human RPE cells","volume":"110\u2013111","author":"Hytti","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112652_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.144558","article-title":"Impact of structurally diverse BET inhibitors on SIRT1","volume":"741","author":"Tenhunen","year":"2020","journal-title":"Gene"},{"key":"10.1016\/j.biopha.2022.112652_bib17","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1186\/s12885-015-1693-z","article-title":"Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent \u03b3-H2AX and telomerase regulation in triple-negative breast cancer","volume":"15","author":"Kala","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2022.112652_bib18","first-page":"1372","article-title":"Processing of gene expression data generated by quantitative real-time RT-PCR","volume":"32","author":"Muller","year":"2002","journal-title":"Biotechniques"},{"key":"10.1016\/j.biopha.2022.112652_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/215496","article-title":"Signatures of drug sensitivity in nonsmall cell lung cancer","volume":"2011","author":"Gong","year":"2011","journal-title":"Int. J. Proteom."},{"key":"10.1016\/j.biopha.2022.112652_bib20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.biopha.2022.112652_bib21","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.2147\/CMAR.S166946","article-title":"Associations of sirtuins with clinicopathological parameters and prognosis in non-small cell lung cancer","volume":"10","author":"Gong","year":"2018","journal-title":"Cancer Manag. Res"},{"key":"10.1016\/j.biopha.2022.112652_bib22","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1080\/15384101.2016.1189041","article-title":"Increased expression of SIRT2 is a novel marker of cellular senescence and is dependent on wild type p53 status","volume":"15","author":"Anwar","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.biopha.2022.112652_bib23","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201643879","article-title":"Sirt1 protects from K-Ras-driven lung carcinogenesis","volume":"19","author":"Costa-Machado","year":"2018","journal-title":"EMBO Rep."},{"key":"10.1016\/j.biopha.2022.112652_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124670","article-title":"Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients","volume":"10","author":"Grbesa","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.112652_bib25","doi-asserted-by":"crossref","first-page":"66343","DOI":"10.18632\/oncotarget.18494","article-title":"The prognostic role of Sirt1 expression in solid malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.112652_bib26","article-title":"SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.112652_bib27","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2147\/OTT.S137146","article-title":"SIRT1 overexpression protects non-small cell lung cancer cells against osteopontin-induced epithelial-mesenchymal transition by suppressing NF-\u03baB signaling","volume":"11","author":"Li","year":"2018","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.biopha.2022.112652_bib28","doi-asserted-by":"crossref","first-page":"62537","DOI":"10.18632\/oncotarget.19244","article-title":"Prognostic and clinicopathological significance of SIRT1 expression in NSCLC: a meta-analysis","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.112652_bib29","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2147\/OTT.S82378","article-title":"SIRT1 expression is associated with poor prognosis of lung adenocarcinoma","volume":"8","author":"Li","year":"2015","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.biopha.2022.112652_bib30","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1515\/hsz-2014-0284","article-title":"SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A","volume":"396","author":"Xu","year":"2015","journal-title":"Biol. Chem."},{"key":"10.1016\/j.biopha.2022.112652_bib31","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1080\/15384101.2019.1634953","article-title":"The sirtuin family in cancer","volume":"18","author":"Costa-Machado","year":"2019","journal-title":"Cell Cycle"},{"key":"10.1016\/j.biopha.2022.112652_bib32","first-page":"1113","article-title":"The cancer genome atlas pan-cancer analysis project","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nat. Genet"},{"key":"10.1016\/j.biopha.2022.112652_bib33","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3389\/fonc.2020.01721","article-title":"The clinical significance of sirt2 in malignancies: a tumor suppressor or an oncogene?","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2022.112652_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2013.05.013","article-title":"Regulation of SIRT2 levels for human non-small cell lung cancer therapy","volume":"82","author":"Li","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.biopha.2022.112652_bib35","first-page":"943","article-title":"miR\u2011150 promotes the proliferation and migration of non\u2011small cell lung cancer cells by regulating the SIRT2\/JMJD2A signaling pathway","volume":"40","author":"Jiang","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2022.112652_bib36","doi-asserted-by":"crossref","first-page":"80336","DOI":"10.18632\/oncotarget.12015","article-title":"SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status","volume":"7","author":"Song","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.112652_bib37","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3892\/ijo.2017.3868","article-title":"SIRT3 is correlated with the malignancy of non-small cell lung cancer","volume":"50","author":"Xiong","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2022.112652_bib38","first-page":"4774","article-title":"Sirtuin SIRT6 suppresses cell proliferation through inhibition of Twist1 expression in non-small cell lung cancer","volume":"7","author":"Han","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.biopha.2022.112652_bib39","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1177\/0300060517750298","article-title":"Downregulation of SIRT6 is associated with poor prognosis in patients with non-small cell lung cancer","volume":"46","author":"Zhu","year":"2018","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.biopha.2022.112652_bib40","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1016\/j.ygeno.2020.04.027","article-title":"Silencing Sirtuin 6 induces cell cycle arrest and apoptosis in non-small cell lung cancer cell lines","volume":"112","author":"Krishnamoorthy","year":"2020","journal-title":"Genomics"},{"key":"10.1016\/j.biopha.2022.112652_bib41","doi-asserted-by":"crossref","first-page":"964","DOI":"10.7150\/ijbs.15165","article-title":"Selecting cells for bioartificial liver devices and the importance of a 3D culture environment: a functional comparison between the HepaRG and C3A cell lines","volume":"12","author":"van Wenum","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biopha.2022.112652_bib42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.21037\/tcr.2018.02.14","article-title":"Genomic alterations across six hepatocellular carcinoma cell lines by panel-based sequencing","volume":"7","author":"Zhao","year":"2018","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.biopha.2022.112652_bib43","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.18632\/oncotarget.6275","article-title":"Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.112652_bib44","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3389\/fonc.2019.01471","article-title":"Targeting BET proteins With a PROTAC molecule elicits potent anticancer activity in HCC cells","volume":"9","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2022.112652_bib45","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3390\/ijms21041297","article-title":"Inhibition of bromodomain and extraterminal domain (BET) proteins by JQ1 unravels a novel epigenetic modulation to control lipid homeostasis","volume":"21","author":"Tonini","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.112652_bib46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fnut.2019.00148","article-title":"SIRT1 in the development and treatment of hepatocellular carcinoma","volume":"6","author":"Farcas","year":"2019","journal-title":"Front. Nutr."},{"key":"10.1016\/j.biopha.2022.112652_bib47","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1158\/0008-5472.CAN-10-4274","article-title":"Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth","volume":"71","author":"Chen","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2022.112652_bib48","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/hep.26278","article-title":"SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B\/glycogen synthase kinase-3\u03b2\/\u03b2-catenin signaling","volume":"57","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.112652_bib49","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccr.2011.09.004","article-title":"SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC\/C activity","volume":"20","author":"Kim","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2022.112652_bib50","first-page":"978","article-title":"The expression of SIRT3 in primary hepatocellular carcinoma and the mechanism of its tumor suppressing effects","volume":"21","author":"Liu","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2022.112652_bib51","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/onc.2015.121","article-title":"Sirtuin 3 inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3\u03b2\/BCL2-associated X protein-dependent apoptotic pathway","volume":"35","author":"Song","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2022.112652_bib52","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1995-7645(13)60112-1","article-title":"SIRT3 expression in hepatocellular carcinoma and its impact on proliferation and invasion of hepatoma cells","volume":"6","author":"Zhang","year":"2013","journal-title":"Asian Pac. J. Trop. Med."},{"key":"10.1016\/j.biopha.2022.112652_bib53","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12885-020-06822-4","article-title":"Modulation of SIRT3 expression through CDK4\/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells","volume":"20","author":"Jo","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2022.112652_bib54","doi-asserted-by":"crossref","first-page":"50117","DOI":"10.18632\/oncotarget.10319","article-title":"Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1\/JNK signaling pathway","volume":"7","author":"Tao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.112652_bib55","article-title":"Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.112652_bib56","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3892\/mmr.2013.1879","article-title":"Sirt6 suppresses hepatocellular carcinoma cell growth via inhibiting the extracellular signal regulated kinase signaling pathway","volume":"9","author":"Zhang","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2022.112652_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2013.35","article-title":"Epigenetic and genetic features of 24 colon cancer cell lines","volume":"2","author":"Ahmed","year":"2013","journal-title":"Oncogenesis"},{"key":"10.1016\/j.biopha.2022.112652_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110701","article-title":"Effects of galloflavin and ellagic acid on sirtuin 6 and its anti-tumorigenic activities","volume":"131","author":"Rahnasto-Rilla","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2022.112652_bib59","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1479-5876-9-202","article-title":"Gut microbiota and sirtuins in obesity-related inflammation and bowel dysfunction","volume":"9","author":"Lakhan","year":"2011","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2022.112652_bib60","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12866-018-1232-6","article-title":"Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis: a case-control study","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.biopha.2022.112652_bib61","doi-asserted-by":"crossref","first-page":"16540","DOI":"10.1038\/s41598-018-34728-6","article-title":"Sirtuin 1 genetic variation, energy balance and colorectal cancer risk by sex and subsite in the Netherlands Cohort Study","volume":"8","author":"Simons","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.112652_bib62","doi-asserted-by":"crossref","first-page":"62589","DOI":"10.18632\/oncotarget.19880","article-title":"Meta-analysis of SIRT1 expression as a prognostic marker for overall survival in gastrointestinal cancer","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.112652_bib63","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijsu.2016.01.002","article-title":"Clinicopathological significance of SIRT1 expression in colorectal cancer: a systematic review and meta analysis","volume":"26","author":"Zu","year":"2016","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.biopha.2022.112652_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2017.01.008","article-title":"SIRT2 mediated antitumor effects of shikonin on metastatic colorectal cancer","volume":"797","author":"Zhang","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112652_bib65","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41419-018-1260-z","article-title":"Inhibition of SIRT2 limits tumour angiogenesis via inactivation of the STAT3\/VEGFA signalling pathway","volume":"10","author":"Hu","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2022.112652_bib66","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.biopha.2018.06.070","article-title":"Sirtuin 6 inhibits colon cancer progression by modulating PTEN\/AKT signaling","volume":"106","author":"Tian","year":"2018","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2022.112652_bib67","doi-asserted-by":"crossref","DOI":"10.14440\/jbm.2015.63","article-title":"In vitro and in vivo model systems used in prostate cancer research","volume":"2","author":"Cunningham","year":"2015","journal-title":"J. Biol. Methods"},{"key":"10.1016\/j.biopha.2022.112652_bib68","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8820355","article-title":"The SIRT3 and SIRT6 promote prostate cancer progression by inhibiting necroptosis-mediated innate immune response","volume":"2020","author":"Fu","year":"2020","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.biopha.2022.112652_bib69","doi-asserted-by":"crossref","first-page":"26494","DOI":"10.18632\/oncotarget.4764","article-title":"SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K\/Akt pathway","volume":"6","author":"Quan","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.112652_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2018.03.023","article-title":"SIRT1 and microRNAs: the role in breast, lung and prostate cancers","volume":"367","author":"Karbasforooshan","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.biopha.2022.112652_bib71","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s13238-013-3054-5","article-title":"Inhibition of SIRT6 in prostate cancer reduces cell viability and increases sensitivity to chemotherapeutics","volume":"4","author":"Liu","year":"2013","journal-title":"Protein Cell"},{"key":"10.1016\/j.biopha.2022.112652_bib72","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/pros.22592","article-title":"SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells","volume":"73","author":"Lovaas","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.biopha.2022.112652_bib73","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bbrc.2008.06.045","article-title":"A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells","volume":"373","author":"Kojima","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2022.112652_bib74","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1074\/jbc.M807869200","article-title":"Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition?","volume":"284","author":"Jung-Hynes","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.112652_bib75","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.yexcr.2018.01.036","article-title":"SIRT3 inhibits prostate cancer metastasis through regulation of FOXO3A by suppressing Wnt\/\u03b2-catenin pathway","volume":"364","author":"Li","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.biopha.2022.112652_bib76","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1021\/acschembio.6b01035","article-title":"Identifying dysregulated epigenetic enzyme activity in castrate-resistant prostate cancer development","volume":"12","author":"Lee","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.biopha.2022.112652_bib77","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.biopha.2022.112652_bib78","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1007\/s13277-015-4231-3","article-title":"SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer","volume":"37","author":"Jin","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.biopha.2022.112652_bib79","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1530\/JOE-11-0217","article-title":"Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer","volume":"213","author":"Moore","year":"2012","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.biopha.2022.112652_bib80","doi-asserted-by":"crossref","first-page":"6654","DOI":"10.1158\/0008-5472.CAN-11-1446","article-title":"SIRT1 is essential for oncogenic signaling by estrogen\/estrogen receptor \u03b1 in breast cancer","volume":"71","author":"Elangovan","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2022.112652_bib81","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/JOE-12-0102","article-title":"SIRT1 represses estrogen-signaling, ligand-independent ER\u03b1-mediated transcription, and cell proliferation in estrogen-responsive breast cells","volume":"216","author":"Moore","year":"2013","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.biopha.2022.112652_bib82","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.celrep.2016.10.006","article-title":"The SIRT2 deacetylase stabilizes slug to control malignancy of basal-like breast cancer","volume":"17","author":"Zhou","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2022.112652_bib83","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/sj.bjc.6603384","article-title":"Altered sirtuin expression is associated with node-positive breast cancer","volume":"95","author":"Ashraf","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2022.112652_bib84","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1159\/000366401","article-title":"The SIRT 3 expression profile is associated with pathological and clinical outcomes in human breast cancer patients","volume":"34","author":"He","year":"2014","journal-title":"Cell Physiol. Biochem."},{"key":"10.1016\/j.biopha.2022.112652_bib85","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.humpath.2014.01.004","article-title":"Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer","volume":"45","author":"Desouki","year":"2014","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.biopha.2022.112652_bib86","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1016\/j.ajpath.2016.08.007","article-title":"CK2\u03b1\/CSNK2A1 phosphorylates SIRT6 and is involved in the progression of breast carcinoma and predicts shorter survival of diagnosed patients","volume":"186","author":"Bae","year":"2016","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2022.112652_bib87","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/carcin\/bgt098","article-title":"SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer","volume":"34","author":"Khongkow","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.biopha.2022.112652_bib88","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1002\/jcb.25171","article-title":"The RUNX2 transcription factor negatively regulates SIRT6 expression to alter glucose metabolism in breast cancer cells","volume":"116","author":"Choe","year":"2015","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.biopha.2022.112652_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3324\/haematol.2017.182675","article-title":"The role of SIRT6 in tumors","volume":"103","author":"Desantis","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2022.112652_bib90","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3389\/fgene.2019.00879","article-title":"Comprehensive analysis of expression and prognostic value of sirtuins in ovarian cancer","volume":"10","author":"Sun","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.biopha.2022.112652_bib91","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3892\/mmr.2017.6183","article-title":"Reduced expression of SIRT2 in serous ovarian carcinoma promotes cell proliferation through disinhibition of CDK4 expression","volume":"15","author":"Du","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2022.112652_bib92","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3892\/ijo.2016.3552","article-title":"SIRT3 participates in glucose metabolism interruption and apoptosis induced by BH3 mimetic S1 in ovarian cancer cells","volume":"49","author":"Xiang","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2022.112652_bib93","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1080\/00313020902884451","article-title":"Expression and prognostic significance of SIRT1 in ovarian epithelial tumours","volume":"41","author":"Jang","year":"2009","journal-title":"Pathology"},{"key":"10.1016\/j.biopha.2022.112652_bib94","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.3892\/ol.2017.6714","article-title":"Low expression of microRNA-1908 predicts a poor prognosis for patients with ovarian cancer","volume":"14","author":"Teng","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.biopha.2022.112652_bib95","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.tranon.2017.05.005","article-title":"SIRT1 regulates the chemoresistance and invasiveness of ovarian carcinoma cells","volume":"10","author":"Mvunta","year":"2017","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.biopha.2022.112652_bib96","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-12-0977","article-title":"c-Myc and cancer metabolism","volume":"18","author":"Miller","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2022.112652_bib97","first-page":"1023","article-title":"Interplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic reprogramming","volume":"7","author":"Zwaans","year":"2014","journal-title":"Dis. Model Mech."},{"key":"10.1016\/j.biopha.2022.112652_bib98","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1242\/jcs.182873","article-title":"RAS isoforms and mutations in cancer at a glance","volume":"129","author":"Hobbs","year":"2016","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.biopha.2022.112652_bib99","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1158\/1535-7163.MCT-15-0037","article-title":"Sensitivity of small cell lung cancer to BET inhibition is mediated by regulation of ASCL1 gene expression","volume":"14","author":"Lenhart","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2022.112652_bib100","doi-asserted-by":"crossref","first-page":"19408","DOI":"10.1073\/pnas.1216363109","article-title":"Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins","volume":"109","author":"Lockwood","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.112652_bib101","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.tranon.2017.09.006","article-title":"Downregulation of SIRT2 inhibits invasion of hepatocellular carcinoma by inhibiting energy metabolism","volume":"10","author":"Huang","year":"2017","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.biopha.2022.112652_bib102","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3390\/cancers13061438","article-title":"Deacetylase plus bromodomain inhibition downregulates ERCC2 and suppresses the growth of metastatic colon cancer cells","volume":"13","author":"Kapoor","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2022.112652_bib103","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1158\/1078-0432.CCR-16-0453","article-title":"The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2022.112652_bib104","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1158\/0008-5472.CAN-18-3223","article-title":"BET inhibitors potentiate chemotherapy and killing of spop-mutant colon cancer cells via induction of DR5","volume":"79","author":"Tan","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2022.112652_bib105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41419-018-0354-y","article-title":"Co-inhibition of BET proteins and NF-\u03baB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions","volume":"9","author":"Wu","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2022.112652_bib106","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nature13229","article-title":"Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer","volume":"510","author":"Asangani","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.112652_bib107","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1172\/JCI126327","article-title":"Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1","volume":"130","author":"Wang","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2022.112652_bib108","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1038\/s41388-019-0815-5","article-title":"BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer","volume":"38","author":"Coleman","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2022.112652_bib109","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.18632\/oncotarget.1572","article-title":"Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer","volume":"4","author":"Wyce","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.112652_bib110","doi-asserted-by":"crossref","first-page":"900","DOI":"10.21037\/tau-21-53","article-title":"The effects of histone crotonylation and bromodomain protein 4 on prostate cancer cell lines","volume":"10","author":"Xu","year":"2021","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.biopha.2022.112652_bib111","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1158\/1541-7786.MCR-19-0393","article-title":"Distinct roles for BET family members in estrogen receptor \u03b1 enhancer function and gene regulation in breast cancer cells","volume":"17","author":"Murakami","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.biopha.2022.112652_bib112","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.celrep.2014.06.016","article-title":"Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription","volume":"8","author":"Nagarajan","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2022.112652_bib113","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10549-015-3319-1","article-title":"Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement","volume":"150","author":"Sengupta","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.biopha.2022.112652_bib114","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.celrep.2015.03.037","article-title":"Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains","volume":"11","author":"Stuhlmiller","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2022.112652_bib115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/onc.2016.184","article-title":"The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer","volume":"36","author":"Da Motta","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2022.112652_bib116","doi-asserted-by":"crossref","first-page":"23756","DOI":"10.1074\/jbc.M116.738666","article-title":"Bromodomain and extraterminal protein inhibition blocks growth of triple-negative breast cancers through the suppression of aurora kinases","volume":"291","author":"Sahni","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.112652_bib117","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.phrs.2017.11.015","article-title":"Targeting bromodomain and extraterminal proteins in breast cancer","volume":"129","author":"Sahni","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2022.112652_bib118","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ccell.2015.05.006","article-title":"Kinase and BET inhibitors together clamp inhibition of PI3K signaling and overcome resistance to therapy","volume":"27","author":"Stratikopoulos","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2022.112652_bib119","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1158\/1535-7163.MCT-16-0004","article-title":"In silico analysis guides selection of BET Inhibitors for triple-negative breast cancer treatment","volume":"15","author":"P\u00e9rez-Pe\u00f1a","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2022.112652_bib120","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41418-019-0353-2","article-title":"Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail","volume":"27","author":"Lu","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2022.112652_bib121","doi-asserted-by":"crossref","first-page":"219","DOI":"10.7150\/thno.13178","article-title":"BET bromodomain inhibition as a therapeutic strategy in ovarian cancer by downregulating FoxM1","volume":"6","author":"Zhang","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2022.112652_bib122","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2019.11.017","article-title":"JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK\/STAT signalling pathway in ovarian cancer","volume":"126","author":"Bagratuni","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2022.112652_bib123","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.18632\/oncotarget.3126","article-title":"JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer","volume":"6","author":"Qiu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.112652_bib124","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41389-021-00316-z","article-title":"Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4","volume":"10","author":"Calder","year":"2021","journal-title":"Oncogenesis"},{"key":"10.1016\/j.biopha.2022.112652_bib125","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.271","article-title":"Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents","volume":"7","author":"Klingbeil","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2022.112652_bib126","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","article-title":"BET proteins as targets for anticancer treatment","volume":"8","author":"Stathis","year":"2018","journal-title":"Cancer Disco"},{"key":"10.1016\/j.biopha.2022.112652_bib127","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1158\/1078-0432.CCR-12-3904","article-title":"Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer","volume":"19","author":"Shimamura","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2022.112652_bib128","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4155\/fmc.14.44","article-title":"Sirtuin inhibitors as anticancer agents","volume":"6","author":"Hu","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.biopha.2022.112652_bib129","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.biocel.2011.07.006","article-title":"Sirt1 deacetylates c-Myc and promotes c-Myc\/Max association","volume":"43","author":"Mao","year":"2011","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.biopha.2022.112652_bib130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002135","article-title":"SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability","volume":"7","author":"Marshall","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.biopha.2022.112652_bib131","first-page":"1023","article-title":"Interplay between Sirtuins, MYC and hypoxia-inducible factor in cancer associated metabolic reprogramming","volume":"7","author":"Zwaans","year":"2014","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.biopha.2022.112652_bib132","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1083\/jcb.200809167","article-title":"A c-Myc-SIRT1 feedback loop regulates cell growth and transformation","volume":"185","author":"Yuan","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.biopha.2022.112652_bib133","article-title":"Regulation of MYC expression and differential JQ1 sensitivity in cancer cells","volume":"10","author":"Fowler","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.112652_bib134","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1158\/1541-7786.MCR-13-0040-T","article-title":"HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS","volume":"11","author":"Yang","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.biopha.2022.112652_bib135","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fphar.2017.00199","article-title":"Honokiol induces apoptosis, G1 arrest, and autophagy in KRAS mutant lung cancer cells","volume":"8","author":"Luo","year":"2017","journal-title":"Front. Pharmacol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222000403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222000403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:43:53Z","timestamp":1760100233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222000403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":135,"alternative-id":["S0753332222000403"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112652","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profiling the regulatory interplay of BET bromodomains and Sirtuins in cancer cell lines","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112652"}}